All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

By GlobeNewswire

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).

Ionis is a commercial and clinical-stage drug company. IONS’ leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone’s triglycerides in adults with hypertriglyceridemia (sHTG).

Before the market opened on November 9, 2026, IONS announced good third quarter 2026 results but said TRYNGOLZA sales for sHTG had “been more gradual than anticipated…we have identified clear opportunities to improve performance.” Third quarter TRYNGOLZA sales were just $9 million and management lowered its full-year TRYNGOLZA sale guidance to $50 million from $100 - $110 million. Management kept total company 2026 revenue guidance in place. On this news, IONS’ stock price plummeted $8.42 per share to $31.00, a drop of 21.4% on very heavy volume.

Investors who suffered losses trading in Ionis common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com.

Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com.

May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.

Wolf Popper LLP
Adam Savett. Esq.
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: asavett@wolfpopper.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.